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ABSTRACT
Several epidemiological changes have occurred in the pattern of nosocomial and community acquired infectious dis-
eases during the past 25 years. Social and demographic changes possibly related to this phenomenon include a rapid
population growth, the increase in urban migration and movement across international borders by tourists and immi-
grants, alterations in the habitats of animals and arthropods that transmit disease, as well as the raise of patients with
impaired host defense abilities. Continuous surveillance programs of emergent pathogens and antimicrobial resistance
are warranted for detecting in real time new pathogens, as well as to characterize molecular mechanisms of resistance.
In order to become more effective, surveillance programs of emergent pathogens should be organized as a multicenter
laboratory network connected to the main public and private infection control centers. Microbiological data should be
integrated to guide therapy, adapting therapy to local ecology and resistance patterns. This paper presents an overview
of data generated by the Division of Infectious Diseases, Federal University of São Paulo, along with its participation
in different surveillance programs of nosocomial and community acquired infectious diseases.
Key words: emerging infectious diseases, HIV, AIDS, candidemia, antimicrobial resistance, bacteremia, sepsis, noso-
comial infectious.
INTRODUCTION
Since the development of antimicrobial drugs against
bacteria, fungi, virus and protozoa, resistance has been
a major concern, particularly after the widespread use of
antibiotics in clinical settings. Failure of conventional
therapy of infectious diseases is obviously responsible
for high morbidity and mortality rates in different pop-
ulations, in addition to the increase of costs of health
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assistance, particularly when new and generally highly
expensive antimicrobial drugs need to be incorporated
with the clinical practice.
Continuous surveillance programs of emergent
pathogens and antimicrobial resistance studying clinical
isolates representative from different geographic areas
are necessary for detecting in real time new pathogens,
as well as to characterize molecular mechanisms of re-
sistance. In order to be more effective, surveillance pro-
grams should be organized as a multicenter laboratory
network connected to the main epidemiological public
and private infection control centers, helping the health
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care community to optimize the introduction of effective
measures for infection control and prevention.
At the Infectious Diseases Division of the Federal
University of São Paulo (UNIFESP), we have organized
and/or actively participated in different surveillance
programs of bacterial, fungi and viral infections. Three
laboratories of our division have been granted interna-
tional excellence level with important contributions:
Special Microbiology Laboratory, Special Micology
Laboratory and Retrovirology Laboratory.
SPECIAL MICROBIOLOGY LABORATORY-UNIFESP:
SURVEILLANCE PROGRAMS OF NOSOCOMIAL
BACTERIAL INFECTIONS
EPIDEMIOLOGY OF NOSOCOMIAL INFECTIONS DUE TO
METHICILLIN-RESISTANT Staphylococcus aureus
Created in 1990, The Special Microbiology Laboratory
has been part and/or has organized several multicen-
ter surveillance studies of bacterial resistance, includ-
ing community acquired and nosocomial infections with
more than 50,000 bacterial samples collected from dif-
ferent sites of infection and colonization.
Methicillin-resistant Staphylococcus aureus
(MRSA) has been the major nosocomial infections
agent since the 80’s of the last century. One of the
clinical settings with higher risk of acquiring MRSA
infections presenting considerable morbidity and mor-
tality rates are represented by the chronic renal patients
under peritoneal or hemodialysis. In São Paulo, we eval-
uated the epidemiology of colonization and infecton
by Staphylococcus aureus in these particular setting of
patients by using molecular typing methods (Pignatari et
al. 1990, 1991) contributing for the implementation of
nosocomial infection control measures at our university
hospital, the Hospital São Paulo (Sesso et al. 1998).
At the beginning of the 90’s, after conducting an
epidemiological study in 8 hospitals of the city of São
Paulo, we detected the dissemination of strains with a
specific DNA macrorestriction profile generated by
pulsed field gel electrophoresis (PFGE) that we named
“SP clone”. This clone was further identified as the
Brazilian Epidemic Clone (BEC), one of the five global
major clones that still occurs nowadays in South Amer-
ica (Sader et al. 1994).
The “BEC clone” was well studied in its micro-
biology, clinical and epidemiological aspects. We ob-
served a high lethality rate, increasing of costs and time
of hospitalization associated with blood stream infec-
tions due to this particular pathogen when compared
to infections caused by methicillin susceptible strains
(Moreira et al. 1998). In addition, we detected in a
MRSA-BEC strain a decrease in its phagocytosis and
killing by neutrophils and monocytes when compared
with the susceptible isolates (Salgado et al. 2004).
Concerns of the scientific and clinical community
increased substantially with the likely of dissemination
of the BEC clone to the community, particularly among
children. A study recently performed with children of
the city of Goiania, Brazil, addressed this issue and de-
monstrated that the dissemination of BEC in this par-
ticular population is rare (Lamaro-Cardoso et al. 2007).
Lately, investigators performing a molecular characteri-
zation of the mec staphylococcal gene cassete (SCCmec)
from episodes of community acquired infections found
the dissemination of methicillin resistant strains within
the community exhibiting highly virulent clones that
were not genetically related to the hospital acquired
ones, such as the BEC (type III SCCmec) in Brazil.
This new phenomenon of dissemination of community-
acquired-MRSA is increasing rapidly in the USA and
Europe (Stryjewski and Chambers 2008). In order to
investigate if this MRSA community acquired infec-
tion is occurring in Latin America, we tested a large
collection of 6,739 MRSA strains isolated from 1997
to 2006 at clinical centers in Brazil, Chile and Argen-
tina. We observed the introduction of new clones of
MRSA, specially the pediatric type IV SCCmec, both
at the community and at the hospital. This finding has
clinical impact regarding clinical practice once that this
new clone is more susceptible to other groups of non
beta-lactams antibiotics compared with the BEC clone.
In the other hand, they may be more virulent if pro-
ducing toxins such as the Panton-Valentine leukocidin
(S.S. Andrade, unpublished data).
CONTRIBUTIONS OF THE SPECIAL MICROBIOLOGY
LABORATORY-UNIFESP TO THE SENTRY:
FOCUS IN BRAZIL AND LATIN AMERICA
Considering our expertise in conducting surveillance
studies in Brazil, we were invited in 1996 to coordi-
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nate the Latin America branch of one of the most im-
portant resistance surveillance programs worldwide, the
SENTRY program. The goal of this program is to deter-
mine geographic and temporal trends in the antimicro-
bial susceptibility profiles of the main pathogens caus-
ing community and nosocomial infections. The bacte-
rial strains are collected prospectively at hospitals and
laboratories enrolled as sentinel centers which are or-
ganized in an international surveillance network from
five continents, with the coordinator center located at
the State of Iowa, USA. In Latin America, several cen-
ters have participated in this program, including insti-
tutions from Mexico, Venezuela, Chile, Colombia and
Brazil (São Paulo, Florianópolis, Porto Alegre and Bra-
sília). Several reports of the SENTRY program have
been published through more than 10 years of collab-
oration. In 2004, we reported the in vitro activity of
several antimicrobial agents against more than 20,000
clinical isolates collected from different medical centers
in Latin America (Sader et al. 2004). These data have
been used to guide empirical therapy and the local im-
plementation of measures for infection control and pre-
vention. Our data supports the conclusion that antimi-
crobial resistance of Gram-negative bacteria seems to
be higher in Latin America as compared to other re-
gions of the world, particularly North America and
Europe. Multi-drug resistance among Gram-negative
bacilli was particularly observed in Acinetobacter bau-
mannii and Pseudomonas aeruginosa strains. For Pseu-
domonas aeruginosa, the Brazilians centers exhibited
the highest rates of resistance documented worldwide.
In addition, the Brazilian rate of Enterobacteriaceae
producing expanded spectrum B lactamase (ESBL) was
higher than that documented in any other country. On
the other hand, vancomycin-resistant enterococci (VRE)
and penicillin-resistant pneumococci are less frequently
described in Latin America (Jones 2001, Andrade et
al. 2003).
The Sentry program has also provided some data
on the evaluation of community acquired infections,
such as the surveillance of E. coli resistance to the anti-
microbial group of quinolones in urinary tract infec-
tions. This type of information is relevant for establish-
ing concepts of adequacy of empirical therapy in this
particular clinical setting (Andrade et al. 2006, Casta-
nheira et al. 2007).
CONTRIBUTIONS OF THE SPECIAL MICROBIOLOGY
LABORATORY-UNIFESP TO THE CHARACTERIZATION
OF NEW MECHANISM OF GRAM-NEGATIVE
RESISTANCE TO CARBAPENENS
As previously stated, multidrug resistance among Aci-
netobacter baumannii and Pseudomonas aeruginosa
strains, particularly to the potent group of beta-lactam
antibiotics carbapenems, is rising rapidly in Brazil. In-
vasive infections caused by the both mentioned species
of bacteria are usually only susceptible to the antimicro-
bial group of polymyxins and are responsible for high
morbidity and mortality rates among hospitalized pa-
tients (Furtado et al. 2007). The mechanism of resis-
tance to carbapenems was originally described as re-
lated to the loss of a membrane porine, impairing the
transportation of the drug to its target of action. New
mechanisms of resistance have been investigated, in-
cluding the production of metallo-beta-lactamase coded
by a gene carried by integrons, as reported since the
90’s in Japan and Italy.
Recently, investigators of our group contributed
to the detection and characterization of a new metallo-
betalactamase gene blaspm reponsible for the productionof an enzyme that inactivates carbapenems (Toleman et
al. 2002). This gene is not carried by integrons, but
has been detected in plasmid, allowing a more effective
horizontal dissemination among strains of Pseudomonas
aeruginosa. In addition, we observed a clonal dissem-
ination of Pseudomonas aeruginosa carrying blaspm inmedical centers from Brazil (Gales et al. 2003). The
rapid identification of carbapenem resistance in these
bacteria, particularly from blood stream cultures, is of
paramount importance in terms of clinical care. In this
way, we recently published a rapid protocol for detec-
tion of metallo-beta-lactamases encoding genes by mul-
tiplex real-time PCR (Mendes et al. 2007).
SPECIAL MYCOLOGY LABORATORY-UNIFESP:
SURVEILLANCE PROGRAMS OF HEMATOGENOUS
INFECTIONS DUE TO CANDIDA SPP.
Candidemia is a growing problem in tertiary care hos-
pitals all over the world where it is commonly observed
among patients with long-stay hospitalization who have
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been exposed to antibiotics, immunosuppressive ther-
apy, parenteral nutrition and other invasive medical
procedures. Despite all advances in medical practices,
hematogenous candidiais is still considered difficult to
diagnose, leads to prolonged hospitalization, causes a
mortality rate of around 50% and is a financial burden
to health care systems (Colombo et al. 1999, 2006).
The epidemiology of candidemia has been exten-
sively studied in the USA and Europe, but not in most
countries of Latin America. Brazil is an exception, with
information on the incidence rates of candidemia, risk
populations, trends in the species distribution as well
as antifungal resistance being recorded over the last ten
years (Colombo and Guimaraes 2003, Morgan 2005).
THE BURDEN OF CANDIDEMIA IN BRAZILIAN
TERTIARY CARE HOSPITALS
Recently, Colombo et al. coordinated 2 large laborat-
ory based surveillance studies to evaluate the epidemi-
ology (including incidence rates), microbiology, treat-
ment and outcome of candidemia in Brazilian tertiary
care hospitals. One study enrolled 4 large medical cen-
ters in the city of São Paulo, and another one enrolled
11 medical centers in 9 different cities in Brazil. In both
studies, epidemiological and clinical data were system-
atically collected by well trained local investigators who
were asked to file up case report forms with the aid of
a dictionary of terms. Candida isolates collected dur-
ing the study were all sent to a core laboratory located
at the Division of Infectious Diseases – UNIFESP for
further identification and antifungal susceptibility test-
ing. Data generated during the two mentioned multi-
center laboratory based on surveillance studies showed
the incidence rates of candidemia ranging between 1.66
and 2.49/1,000 admissions in Brazilian tertiary care hos-
pitals. These rates are considered 2 to 10 times higher
than those documented in the USA and European medi-
cal centers (Colombo et al. 2006, 2007).
Although the reasons of a higher incidence of can-
didemia in Brazil is not completely understood, it could
be reasonable to suggest that this fact should be related
to differences in resources that are available for medical
care and training programs of healthcare workers to as-
sist critically ill patients, as well as a more conservative
approach to the administration of empirical antifungal
therapies and prophylaxis to patients at high risk for can-
didemia (Colombo et al. 2007).
In terms of susceptible populations, considering
data generated by the mentioned nationwide surveil-
lance of candidemia, 30% of all patients who devel-
oped fungaemia in public tertiary care hospitals in
Brazil were represented by pediatric patients, a signif-
icantly greater proportion as compared to North Ameri-
can and European studies (Hajjeh et al. 2004, Tortorano
et al. 2006). In terms of coexisting exposures, most
adult patients with candidemia were represented by
patients with diabetis and other organ failures who have
been exposed to multiple risk factors including antibio-
tics, parenteral nutrition, central venous catheterization
and other invasive medical procedures. It is worth men-
tioning that, at the time of the diagnosis of candidemia,
46% of the patients were admitted at an intensive care
unit, and 39% of all patients had undergone surgery
up to 30 days before developing candidemia (Colombo
et al. 2006).
Consequences of cutting public funding polices to
the health system on the epidemiology of nosocomial
rates of bloodstream infections have been scarcely dis-
cussed. In order to evaluate if patients treated at hospi-
tals under different levels of financial support exhibit dif-
ferences in the epidemiology of candidemia, we started
a multicenter study to compare 2 public tertiary care
hospitals in Brazil with the data generated by 6 private
hospitals located in São Paulo (1), Rio de Janeiro (3),
Curitiba (1) and Salvador (1). We collected data on the
epidemiology (including incidence rates), microbiology,
treatment and outcome of candidemia using a web-based
case report form, and compared the characteristics of
candidemia in patients from public and private hospi-
tals. Preliminary analysis of data collected during this
study suggest that incidence rates of candidemia (3.04
vs. 1.04/1000 admissions, p< 0.01), as well as mortality
rates (53 × 40%, p = 0.06), were higher in the 2 public
tertiary care hospitals than in the 6 private institutions
(A.L. Colombo et al., unpublished data).
SPECIES DISTRIBUTION OF CANDIDA AND ANTIFUNGAL
RESISTANCE RELATED TO EPISODES OF CANDIDEMIA
Antifungal resistance surveillance programs have been
conducted recently by different groups, and there is
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mounting evidence suggesting that the emergence of in-
vasive infections due to Candida non-albicans (CNA)
species resistant to fluconazole may be an increasing
problem in several medical centers in the world. Fluco-
nazole resistance rates of C. glabrata bloodstream iso-
lates range from 7 to 14% in American hospitals, and
from 3.7 to 40% in European hospitals (Chryssanthou
2001, Diekema et al. 2002, Ostrosky-Zeichner et al.
2003, Hajjeh et al. 2004, Cuenca-Estrella et al. 2005,
Tortorano et al. 2006).
Unlike the epidemiology of North Hemisphere
countries, there is still a predominance of non-albicans
Candida species in Brazil susceptible to fluconazole
represented mostly by C. parapsilosis and C. tropicalis
strains (Colombo et al. 1999, 2006, Antunes et al. 2004,
Aquino et al. 2005). According to most series col-
lected in Brazilian medical centers, candidemia due to
C. glabrata persists at a low frequency accounting for
less than 5% of the candidemic episodes. Recently, by
analyzing the data related to 1000 episodes of candide-
mia documented in 4 public medical centers through-
out a 9-year period, excluding the rising incidence of
C. parapsilosis strains from 1995 to 2003 (19% versus
25%, p = 0.03), there were no changes in the distribu-
tion pattern of Candida species (da Matta et al. 2007).
In terms of antifungal resistance, most concerns
are related to the emergence of non-Candida albicans
species resistant to fluconazole, particularly C. glabrata
and C. krusei. The Special Mycology Laboratory at the
Division of Infectious Diseases-UNIFESP is an active
member of the ARTEMIS Global Antifungal Surveil-
lance Program, a worldwide comprehensive surveillance
network which uses the CLSI M44-A disk diffusion
method with fluconazole discs to capture resistance rates
at 134 different laboratories located in 40 countries.
Our last report documented the antifungal susceptibil-
ity of 205,329 yeast strains against fluconazole tested
from June 1997 to December 2005. According to this
report, 90.1% of all Candida isolates tested were sus-
ceptible (S) to fluconazole. On the other hand, flucona-
zole resistance and dose dependent-susceptibility were
observed with 30% and 90%, respectively, of all C. gla-
brata and C. krusei strains tested (Diekema et al. 2007,
Pfaller et al. 2007). In the last 3 years, we have tested
more than 2,000 Candida bloodstream isolates from dif-
ferent medical centers as part of 3 different multicen-
ter studies. Overall, we found that fluconazole resis-
tance or dose dependent susceptibility occurs in less
than 1% of the C. albicans, C. tropicalis and C. para-
psilosis strains related to fungaemia. Nevertheless, 8 to
50% of all C. glabrata bloodstream isolates tested were
considered susceptible dose dependent or resistant to flu-
conazole, depending on the period and medical centers
evaluated. This finding is similar to data generated by
other groups in Brazil (Colombo et al. 2006, 2007, da
Matta et al. 2007).
MOLECULAR MECHANISMS OF ANTIFUNGAL RESISTANCE
Several groups have attempted to characterize the mo-
lecular mechanisms of antifungal resistance with Can-
dida albicans and some non-Candida albicans strains in
Europe and USA. In Latin America, we were the first
group to investigate the mechanisms related to azole re-
sistance by testing Candida strains isolated from AIDS
patients.
In a collaborative study with Professor Gustavo
Goldman from the Faculdade de Ciências Farmacêuti-
cas de Ribeirão Preto, Universidade de São Paulo, we
described the molecular mechanisms of fluconazole-res-
istance by evaluating C. albicans strains isolated from 9
different medical centers. The C. albicans isolates used
in this study represent a collection of 20 strains which
were obtained from AIDS patients with oral or esopha-
geal candidiasis who received fluconazole during a pe-
riod of 6 to 12 months. The entire open reading frame of
the ERG11 gene encoding lanosterol 14α-demethylase
was sequenced from all C. albicans isolates. In addition,
we evaluated the overexpression of ERG11 and several
genes encoding efflux pumps for azoles by using a quan-
titative real-time RT-PCR (Goldman et al. 2004).
After screening all resistant C. albicans strains, we
found the presence of point mutations in the ERG11
gene, overexpression of ERG11, and genes encoding
efflux pumps such as CDR and MDR, as measured by
quantitative real-time RT-PCR. Several fluconazole-res-
istant strains had multiple mechanisms of resistance.
A total of 4 mutations previously described, Y132F,
K143R, E266D, and V437I, were identified among the
strains, while some isolates contained more than one
mutation (Goldman et al. 2004).
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The mechanisms of azole resistance found in the
Brazilian collection of C. albicans strains resistant to
fluconazole are similar to the results described to date
by other groups. In the case of C. albicans strains, the
fluconazole-resistant phenotype is usually secondary to
the coexistence of multiple mechanisms of resistance.
Of note, new triazoles have been developed, with the aim
of avoiding fluconazole cross resistance. However, cross
resistance to voriconazole and posaconazole has been
extensively reported with C. glabrata and C. albicans
strains (Sanglard et al. 1996, Perea et al. 2001, Sanglard
and Odds 2002, Kanafani and Perfect 2008).
THE BURDEN OF SEPSIS IN BRAZIL AND SOME
STRATEGIES TO DECREASE THE ASSOCIATED
CRUDE MORTALITY
The high incidence of bloodstream infections and sep-
sis has been continuously evaluated in our Institution
by Salomão et al. Between 1985 and 1986, the inci-
dence rate of blood stream infections at the Hospital
São Paulo – Universidade Federal de São Paulo, was
21.7 episodes by 1000 admittances, with a crude mor-
tality rate of 33.4% (Salomão et al. 1992, 1993). A
new survey performed at the same institution in 2004
demonstrated that the incidence rate of BSI increased
to 26.8 per 1000 admissions exhibiting overall mortal-
ity rate of 44% (Segovia, Pereira and Salomão, personal
communication). The increasing incidence of nosoco-
mial sepsis has been discussed by different groups in the
USA, where a large study showed a substantial increase
of BSI caused by bacteria and fungi along the last 20
years (Martin et al. 2003).
Considering the lack of sensitivity of blood cul-
tures, it is reasonable to suggest that laboratory based
surveillance studies may underestimate the true incid-
ence rates of BSI and sepsis. Recently, a Brazilian
multicenter surveillance of sepsis was conducted in
5 intensive care units in São Paulo using as inclusion
criteria laboratory and clinical data for case definition.
This study (BASES – Brazilian Sepsis Epidemiologi-
cal Study) was conducted by Silva et al. between may
2001 and January 2002, obtaining incidence artes of
57.9 episodes of sepsis per 1000 pacients-day, or 30.5
episodes per 100 admissions. The crude mortality rates
of patients with sepsis, severe sepsis and septic shock
were 34.7%, 47.3% and 52.2%, respectively (Silva et
al. 2004).
The burden of sepsis in the USA was evaluated
by a population-based multicenter surveillance study
conducted by Martin et al. (2003) including the evalu-
ation of all hospital admissions between 1979 and 2000.
During this study, it was possible to conclude that
incidence rates of sepsis in the USA raised from 82.7
episodes/100,000 inhabitants in 1979 to 240.4 epis-
odes/100,000 habitants in 2000 (Martin et al. 2003).
In order to decrease the crude mortality of sepsis,
including the concerns with multiresistant pathogens,
we have targeted to main aspects: the challenge to use
appropriate antimicrobial therapy, and the use of strate-
gies to prevent blood stream infections associated with
central venous catheter.
The impact of appropriate therapy in the outcome
of BSI was clearly demonstrated some decades ago. We
have found that appropriateness of antimicrobial ther-
apy, which happen when the bacteria is susceptible to
the antimicrobial administered, has a profound impact
on survival rates of patients with blood stream infection
and sepsis. Overall mortality was 33.4% and it could
be as low as 21% in patients receiving appropriate ther-
apy, and as high as 57.1% in those receiving inappro-
priate therapy. Interestingly, patients who received in-
appropriate therapy and were administered appropriate
therapy thereafter based on cultures results or lack of
clinical responses had intermediate mortality (34.1%).
However, changing antibiotics in patients already with
septic shock did not improve outcomes (Salomão et al.
1993). There is increasing evidence that the delay in
initiating the antimicrobial therapy has profound impact
in mortality. Kumar et al. showed that the duration of
hypotension before initiation of effective antimicrobial
therapy is the critical determinant of survival in human
septic shock (Kumar et al. 2006).
A relevant aspect to be mentioned and monitor-
ed is that nosocomial acquired primary bloodstream
infections are mainly associated with central venous
catheter (CVC-BSI). In a multicenter study, we found
increased device-associated nosocomial infections, in-
cluding CVC-BSI, in Intensive Care Units from devel-
oping countries, as compared to the USA and Europe
(Rosenthal et al. 2006). We succeed to reduce the rates
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of central vascular catheter-associated bloodstream in-
fections in an adult intensive care unit by using educa-
tion and performance feedback (Salomão et al. 2005)
and reached infections rates similar to the developed
countries by switching from an open intravenous infu-
sion system to a closed system (Salomão et al. 2006).
RETROVIROLOGY LABORATORY-UNIFESP:
SURVEILLANCE PROGRAMS OF HIV-1 ESCAPE
AND RESISTANCE
Viruses are ubiquitous and the most prevalent biologi-
cal entity on the planet (Angly et al. 2006, Koonin et al.
2006). However, viruses have constantly to adapt to se-
lective pressures offered by the environment where they
propagate. Some of these pressures are not present in
nature, such as the pressure exerted by antiretroviral
drugs, while others are represented by the host immune
response (Bailey et al. 2004). Viruses employ many
strategies to escape host defenses or other pressures.
Viral evasion strategies enable the virus to avoid recog-
nition by the immune response by changing its epitopes,
to interfere with cellular immune responses by disabling
peptide presentation, to interfere with immune function
by secreting viral encoded cytokines or blocking apop-
tosis, and to interfere with antiviral drug activity by in-
corporating drug resistance mutations (Domingo 1997,
Vossen et al. 2002, Alcami 2003, Peterlin and Trono
2003, Clavel and Hance 2004, Leslie et al. 2004, Smith
2004, Manrubia et al. 2005, Telenti 2005, Martinez-
Picado et al. 2006, Schneidewind et al. 2007). So-
phisticated DNA viruses have a greater genetic back-
ground that allows them to make use of different es-
cape routes, including viral mimicry by incorporation
of cellular genes into their genomes (Chaston and Lid-
bury 2001, Alcami 2003). RNA viruses have smaller
genomes and, due to their highly mutation rates, they
cannot extend their genomes beyond a limit, being un-
able to incorporate new and different coding capacities
into their genomes (Domingo et al. 1996, 2001, 2005,
Domingo 1997, Chaston and Lidbury 2001). RNA
virus relay basically on genetic diversification to escape
elimination by host defenses or chemical pressures. Di-
versification gives rise to viral variants with increased
resistance. Acquisition of resistance leads to diminished
viral fitness (Bleiber et al. 2001, Buckheit 2004, Smith
2004). Viral fitness is generally accepted as the rela-
tive ability of a virus to replicate in a defined environ-
ment, and is used to describe the viral replication poten-
tial in the absence of the selective pressure that origi-
nated resistance.
HIV-1 AND GENETIC DIVERSITY
Global diversity
Almost 30 years since the first cases of the acquired
immunodeficiency syndrome (AIDS), our power to man-
age infected patients or to reach an effective control
of the AIDS pandemic remains limited (Rambaut et al.
2004). According to the 2007 UNIAIDS report, there
are over 30 million people living with HIV today. Al-
though HIV global prevalence has leveled off, and the
number of new infections has decreased, 2.5 million in-
dividuals acquired HIV infection and 2.1 million died of
AIDS in 2007. AIDS is among the leading causes of
death globally and remains the primary cause of death
in Africa (www.uniaids.org). HIV strains are divided
into two types, HIV-1 and HIV-2. HIV-1 strains are re-
sponsible for the global epidemic drive and are classi-
fied in Groups, M, N, and O. Group M encompasses 9
genetic subtypes and more than 40 circulating recom-
binant forms (CRF) (www.hiv.lanl.gov). HIV-1 global
distribution is complex and dynamic, with regional epi-
demics harboring only a subset of the global diversity.
HIV-1 strains differ enormously in terms of global pre-
valence. 6 viral lineages account for the majority of
HIV-1 infections: HIV-1 subtypes A, B, C, D, and two
of the CRFs, CRF01-AE and CRF02_AG, respectively.
Many of the known subtypes and recombinant forms
are currently rare in the epidemic. Groups O and N are
rare in the pandemic (McCutchan et al. 2004, Kijak and
McCutchan 2005, Sa Filho et al. 2005, De Sa Filho et
al. 2006, McCutchan 2006, Sanabani et al. 2006, Taylor
et al. 2008).
HIV-1 SUBTYPES IN BRAZIL
The HIV-1 Brazilian epidemic shows a heterogeneous
distribution of HIV-1 subtypes and recombinants (Sa
Filho et al. 2005, De Sa Filho et al. 2006). The most
prevalent strains belong to subtype B and were the first
introduced in the country in the 1970s. Subtype F strains
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appeared in the 1980s and always accounted for not
much than 10% of all infections. More recently, BF
recombinants are gaining ground even surpassing the
number of subtype F infections. Subtype C strains result
from a later introduction and are prevalent in Southern
Brazil. Besides plain subtypes, a number of CRFs, have
already been identified in Brazil, but their impact on the
epidemic is still not clarified (www.hiv.lanl.gov).
INTRAHOST VIRAL DIVERSITY
In an individual, HIV-1 maintains a rapid evolution
pace resulting from high mutation rates, large popu-
lation sizes, accelerated replication dynamics, and high
recombination frequencies. As a result, HIV popula-
tions correspond to a swarm of mutants harboring differ-
ent mutations, and can be referred to as a quasispecies
(Domingo 1985). Quasispecies arise from a balance
between mutation and natural selection, originating a
population of variant viruses. Viruses in a quasispecies
cannot be seen as independent entities, but as linked by
mutational couplings, with the entire distribution form-
ing a cooperative community that evolves as a single unit
(Duarte et al. 1994, Domingo et al. 1996, 1998, 2001,
2005, 2006, Domingo 1997, Holmes and Moya 2002,
Jenkins et al. 2002). In a quasispecies, natural selection
is no longer directed toward the single fittest variant,
but instead acts on the whole mutant distribution.
Viral mutant distributions may promptly adapt to new
selective pressures due to high mutation rates.
ESCAPE AND RESISTANCE
Escape
The genetic background of different individuals influ-
ences their susceptibility to HIV-1 infection and disease
progression. Differences on viral susceptibility have
been attributed to specific HLA types, chemokines and
chemokine receptor polymorphism. More recently, 2
cellular proteins, APOBEC3G and TRIM5, have been
described as additional antiviral components of the in-
nate immunity (Sheehy et al. 2002) HIV-1 has evolved
strategies against the action of both proteins.
Antibodies are important elements of the immune
response and succeed in controlling several viral infec-
tions. However, HIV-1 is able to replicate continuously
in the presence of a vigorous antibody response. The
HIV-1 genome encodes two envelope glycoproteins:
the transmembrane gp41 anchors the Env complex in
the viral envelope and mediates fusion with the host
cell membrane, while the surface gp120 interacts with
cellular receptors. HIV-1 gp120 is heavily glycosylated
and contains 5 “hypervariable” domains, V1 to V5. HIV-
1 envelope proteins avoid neutralizing antibody by a
number of different strategies. Mechanisms of humoral
escape include: hiding of critical neutralizing epitopes,
extension of gp120 variable loops, conformational pro-
tection of viral receptor binding motifs, and extensive
glycosylation of envelope surface proteins. It has been
demonstrated that acutely infected patients produce
NAbs against autologous virus within months of sero-
conversion (Albert et al. 1990, Tremblay and Wainberg
1990, Richman et al. 2003, Wei et al. 2003, Frost et
al. 2005), but although the early produced NAbs reach
fairly high titers, escape mutants are rapidly selected due
to the ongoing viral replication (Richman et al. 2003,
Wei et al. 2003). It also has been shown that chronically
HIV-1 infected patients develop NAbs against earlier vi-
ral isolates, but they fail to neutralize contemporaneous
virus (Albert et al. 1990, Tremblay and Wainberg 1990,
Skrabal et al. 2005).
Cytotoxic T-lymphocytes (CTL) are important
against HIV-1 (Smith 2004, Betts et al. 2006). CTL de-
stroys HIV infected cells upon recognizing viral pep-
tides bound to class I major histocompatibility complex
(MHC) molecules. Different MHC alleles bind viral
peptides with distinct affinities. MHC alleles, which
bind particular viral peptides strongly, often result in
vigorous cellular responses against those viral epitopes.
Avoidance of cellular responses results in replicative ad-
vantages. Evasion of CTL targeting involves mutations
within and around recognized epitopes, and results in
the lack of peptide binding to the Class I MHC grove,
or non-recognition by the CTL T cell receptor, or inter-
ference with peptide processing (Phillips et al. 1991,
Goulder et al. 1997, Price et al. 1997, Smith 2004). CTL
escape mutations are associated with increased viral
loads and rapid disease progression (Koenig et al. 1995,
Borrow et al. 1997, Goulder et al. 1997). However,
mutations associated with CTL escape cause significant
viral fitness costs. Fitness costs correlated with CTL
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evasion have been demonstrated in patients carrying
the B*57, B*5801, and B*27 HLA alleles (Friedrich
et al. 2004, Smith 2004, Martinez-Picado et al. 2006,
Crawford et al. 2007).
Resistance
Several classes of drugs are used against HIV-1 and tar-
get different steps of the viral replication cycle. They
include: nucleoside analogues, which act as DNA syn-
thesis terminators inhibiting reverse transcription; non-
nucleoside reverse-transcriptase antagonists, which di-
rectly inhibit reverse transcriptase; protease inhibitors
interfering with viral maturation; entry inhibitors includ-
ing CCR5 blocking agents and fusion inhibitors, de-
signed to halt HI1 penetration into permissible cells;
and the newly approved integrase inhibitor that acts
by blocking HIV-1 integration into the cellular genome
(Lucas et al. 1999, Dybul et al. 2002, Kress 2004,
Kuritzkes 2004, Luber 2005, Piacenti 2006, Evering
and Markowitz 2007, Opar 2007, Hendrickson et al.
2008, Lagnese and Daar 2008, Laurence 2008, Strizki
2008). Antiretroviral drugs are used in different com-
binations, usually of 3 antiretroviral drugs, with 2 nu-
cleoside analogues and either a protease or a nonnucle-
oside inhibitor, with regimens starting to feature entry
inhibitors when HIV infection has not been controlled
by other drug combinations (http://www.aidsinfo.nih.gov/
ContentFiles/AdultandAdolescentGL.pdf. Accessed April
19, 2008).The simultaneous use of different drugs is known
as highly active antiretroviral therapy (HAART). The
goal of HAART is to achieve and maintain viral loads
below 50 copies/mL. Suppression below this level is as-
sociated with treatment success, helps immunological
restoration, and difficults the onset of viral resistance.
The development of drug resistance requires the con-
currence of 2 factors: antiretroviral drug exposure and
ongoing viral replication. Initially thought as a cure for
HIV infection (Perelson et al. 1996), today we know
that HAART cannot eradicate HIV-1 (Wong et al. 1997,
Siliciano 1999, Siliciano and Siliciano 2000, Bailey et
al. 2006). Undoubtedly, HAART has increased the
quality of life for HIV-1 infected persons. However,
limitations of HAART started to appear by the identi-
fication of latent HIV-1 reservoirs (Blankson et al.
1999, 2002, Siliciano 1999, Siliciano and Siliciano
2000, 2004, Bailey et al. 2006). These reservoirs act
as viral archives ready to replenish the pool of repli-
cating virus. Although drug therapy is efficient at con-
trolling plasma viral levels, viruses in reservoirs are not
targeted by the drugs. Because viral recombination
was not taken into account, resistance mutations were
thought to accumulate in distinct genomes in an ordered
fashion (Molla et al. 1996). Recombination allows the
virus to exchange resistance mutations in a nonlinear
fashion, leading to rapid evolution leaps of resistant
mutants, even from different reservoirs (Morris et al.
1999, Zhuang et al. 2002, Levy et al. 2004, Charpentier
et al. 2006, Nora et al. 2007). Finally, seminal studies
from patients undergoing HAART wrongly concluded
that the virus was not experiencing evolution if viral
loads were undetectable (Wong et al. 1997, Finzi and
Siliciano 1998). Although not detectable in the plasma,
ongoing viral replication in localized niches would
inevitably lead to the incorporation of mutations, and
some would result in virus with diminished drug suscep-
tibility (Chun et al. 1999, Martinez-Picado et al. 2000).
Evolution of drug resistance reduces our ability to con-
trol HIV-1. Drug therapy failure results from the ac-
cumulation of drug resistance mutations. The genetic
barrier for resistance varies from drug to drug. Resis-
tance to some drugs, as nonnucleoside inhibitors, may
happen after just a brief exposure to the drug. Con-
versely, resistance to protease or nucleoside inhibitors
generally requires the selection of a combination of
mutations (Clavel and Hance 2004, Nettles et al. 2004,
Lucas 2005, Wood et al. 2005, Taylor et al. 2008). Mu-
tation in both protease and reverse transcriptase may
lead to a reduction in viral fitness, with either enzyme
displaying a profound impairment (Bleiber et al. 2001,
Buckheit 2004). Resistance to HIV-1 fusion inhibitors
is also associated with impaired fitness, while resistance
to nonnucleoside reverse transcriptase inhibitors has a
less evident effect on viral replication (Schmit et al. 1996,
Chen et al. 2005). Acquisition of viral drug resistance
generally follows a common series of events: the ini-
tial selection of drug-resistance mutations causing viral
fitness reductions and, subsequently, the introduction of
compensatory mutations enabling the virus to recover
fitness (Bleiber et al. 2001, Buckheit 2004).
Drug-resistant mutations are detected in drug-
naïve patients (Ribeiro et al. 1998, Brumme et al. 2007,
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Smith et al. 2007, Sucupira et al. 2007, Little et al.
2008), but recent data suggest that the prevalence of
drug-resistant HIV in newly diagnosed patients may
have leveled off at approximately 10% over the past
several years (Kuritzkes 2007). However, existence of
HIV drug resistance prior to the initiation of antiretro-
viral therapy can be a major impediment to success-
ful treatment outcomes (Ribeiro et al. 1998, Daar 2007,
Metzner et al. 2007). Data on resistance patterns for
new drugs and new drug classes are beginning to
emerge. All 3 new categories of antiretroviral agents
(chemokine receptor inhibitors, second-generation non-
nucleosides, and integrase inhibitors) have shown vul-
nerability to drug resistance (Kuritzkes 2007). More-
over, minority HIV-1 variants that may not be detected
by current resistance tests may have an impact on treat-
ment, limiting future therapeutic approaches (Metzner
2006, Daar 2007).
HIV-1 RESISTANCE IN BRAZIL
In 1996 the Brazilian Government approved a Federal
law that established an universal access to HAART for
citizens living with HIV-1 (www.aids.gov.br). There are
approximately 185,000 HIV-1 infected individuals re-
ceiving HAART today in Brazil (www.aids.gov.br). Al-
though introduction of HAART has certainly slowed the
disease progression among infected people, some of its
consequences are the emergence of viral resistance and
the transmission of resistant strains. HIV-1 resistance
mutations, to at least one class of drugs, can be detected
in a high percentage of the treatment experienced by
Brazilian individuals (Cavalcanti et al. 2007, De Sa
Filho et al. 2008), but the levels of transmitted resis-
tance are comparable to the ones observed in Europe
and in the United States (Brindeiro et al. 2003). How-
ever, 2 studies indicated much higher primary resist-
ance levels in the coastal cities of Santos and Salvador
(Pedroso et al. 2007, Sucupira et al. 2007). Because
Brazil was a pioneer in Government sponsored broad
drug distribution, there is a constant need to survey HIV-
1 resistance levels in treatment naïve and experienced
individuals living in the country.
FUTURE PERSPECTIVES
We are currently conducting a new nationwide surveil-
lance program of nosocomial blood stream infections
at 15 medical centers located in different regions of
Brazil named SCOPE Brazil (Surveillance and Control
of Pathogens of Epidemiological Importance). This pro-
gram will combine for the first time the efforts of all
investigators of our Divison interested in the evaluation
of nosocomial bloodstream infections, regardless of the
pathogen that causes the disease. We believe that this
is a compreensive and effective program that will con-
tribute to more adequate infection control and antimicro-
bial use of policies in Brazil.
In addition, with the collaboration of Marcio Nucci
from the Federal University of Rio de Janeiro, we are
establishing the Latin American Candidemia Network,
a group of 12 investigators that will conduct a labo-
ratory based surveillance study of candidemia involv-
ing 24 medical centers within 9 different countries in
Latina America.
With respect to HIV infection, considering the
universal access of anti-retroviral drugs in Brazil, it is
mandatory to constantly monitor HIV resistance in our
population. Our Division is currently involved in check-
ing resistance levels in groups of recently infected pa-
tients living in different areas of the country. We have a
number of ongoing countrywide collaborations that al-
low us to collect samples from various locations. Studies
like this one are helping us to gauge the primary rate of
HIV resistance in Brazil. We are also addressing the
stability of drug resistance mutations in naïve patients
that acquired the virus from drug experienced patients.
Furthermore, we are conducting a series of studies on
APOBEC3s polymorphisms encountered in the infected
Brazilian population, and investigating how they influ-
ence the levels of hypermutation on the viral genome.
Finally, we are also constantly surveying the HIV-1 sub-
type distribution in the country monitoring HIV-1 prop-
agation in Brazil. We were the first group identifying
not only one, but two HIV-1 Circulating Recombinant
Forms in the Brazilian epidemic.
RESUMO
Várias alterações epidemiológicas ocorreram no perfil das
doenças infecciosas hospitalares e comunitárias nos últimos
25 anos. Mudanças sociais e demográficas possivelmente rela-
cionadas com esse fenômeno incluem o rápido crescimento
populacional, o aumento da migração urbana e deslocamento
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através de fronteiras internacionais por turistas e imigrantes,
alterações nos habitats de animais e artrópodes que transmitem
doença assim como o aumento no número de pacientes com
deficiências nas respostas de defesa. Os programas contínuos
de vigilância de patógenos emergentes e resistência antimicro-
biana são necessários para a detecção em tempo real de novos
patógenos assim como para caracterizar mecanismos molecu-
lares de resistência. Para serem mais efetivos, os programas
de vigilância dos patógenos emergentes devem ser organiza-
dos em uma rede de laboratórios multicêntricos ligados aos
principais centros de controle de infecções, públicos e priva-
dos. Os dados microbiológicos devem ser integrados a guias
terapêuticos adaptando práticas terapêuticas à ecologia local e
aos padrões de resistência. O artigo apresenta uma revisão
dos dados gerados pela Disciplina de Infectologia, Univer-
sidade Federal de São Paulo, contemplando sua participação
nos diferentes programas de vigilância de doenças infecciosas
hospitalares e adquiridas na comunidade.
Palavras-chave: doenças infecciosas emergentes, HIV, AIDS,
candidemia, resistência antimicrobiana, bacteremia, sepsia,
infecções hospitalares.
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